Treatment With Immunoglobulin And Adverse Events In PID (Primary Immunodeficiency)

被引：0
|
作者：
Puget, Sophie [1 ]
Darnige, Luc [2 ]
机构：
[1] LFB Biomed, Int Sci Affairs Unit, Lublin, Poland
[2] Hosp Europeen Georges Pompidou, AP HP Paris, Haematol Unit, Paris, France
来源：
CLINICAL AND EXPERIMENTAL IMMUNOLOGY | 2015年 / 182卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P43
引用
收藏
页码：20 / 21
页数：2
相关论文
共 50 条
  • [21] PID123 Primary Immunodeficiency
    Liebrich, Walter
    Emanuel, Shaunagh
    Esser, Monika
    CURRENT ALLERGY & CLINICAL IMMUNOLOGY, 2015, 28 (04) : 305 - 307
  • [22] Neutropenia and primary immunodeficiency disease (PID)
    Mattew, S. N.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 119 (01) : S183 - S183
  • [23] MANAGING PRIMARY IMMUNODEFICIENCY IMMUNOGLOBULIN REPLACEMENT THERAPY-RELATED ADVERSE EVENTS: PROPHYLAXIS WITH RECOMBINANT HUMAN C1 ESTERASE INHIBITOR
    Jones, D.
    Memmott, H.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S148 - S148
  • [24] Subcutaneous immunoglobulin 16.5% for the treatment of pediatric patients with primary antibody immunodeficiency
    Gupta, Sudhir
    Kobayashi, Roger H.
    Litzman, Jiri
    Cherwin, Laurel
    Hoeller, Sonja
    Kreuwel, Huub
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2023, 19 (01) : 7 - 17
  • [25] Individualized immunoglobulin treatment in pediatric patients with primary humoral immunodeficiency disease
    Patel, Niraj C.
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2018, 29 (06) : 583 - 588
  • [26] Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
    Skoda-Smith, Suzanne
    Torgerson, Troy R.
    Ochs, Hans D.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2010, 6 : 1 - 10
  • [27] Cost Minimization Analysis of Immunoglobulin Treatment of Primary Immunodeficiency Diseases in Spain
    不详
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2022, 27 (04): : 165 - 165
  • [28] CSL BEHRING CARES: SUPPORTING PATIENTS WITH PRIMARY IMMUNODEFICIENCY (PID) TO USE SUBCUTANEOUS IMMUNOGLOBULIN (HIZENTRA®) IN THE HOME
    Tognarini, David
    Fenton, Kathryn
    Kim, Emilia
    Youssef, Sherif
    INTERNAL MEDICINE JOURNAL, 2022, 52 : 30 - 31
  • [29] Efficacy, Pharmacokinetics And Tolerability Of IQYMUNE®, A Novel 10% Intravenous Immunoglobulin (IVIg), In Patients With Primary Immunodeficiency(PID
    Krivan, Gergely
    Chernyshova, Ludmila
    Kostyuchenko, Larysa
    Lange, Andrzej
    Nyul, Zoltan
    Derfalvi, Beata
    Musial, Jacek
    Bellon, Anne
    Kappler, Martin
    Sadoun, Alain
    Puget, Sophie
    Bernatowska, Ewa
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2015, 182 : 19 - 19
  • [30] Is there a delay in the diagnosis of Primary Immunodeficiency (PID)? The "Is it PID?" Advisory Group
    Grigoriadou, S.
    Iluissoon, A.
    Kumararatne, D.
    Hackett, S.
    Weldon, R.
    Hughan, C.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2010, 160 : 8 - 8
12345